Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP

Despite significant progress in the development of novel STING agonists (STINGa), applications appear to be challenged by the low efficiency and poor selectivity of these agents. A pH Low Insertion Peptide (pHLIP) extends the lifetime of a STINGa in the blood and targets it to acidic cancer-associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Moshnikova, Anna, DuPont, Michael, Visca, Hannah, Engelman, Donald M., Andreev, Oleg A., Reshetnyak, Yana K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622777/
https://www.ncbi.nlm.nih.gov/pubmed/36330464
http://dx.doi.org/10.3389/fonc.2022.1023959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622777/
https://www.ncbi.nlm.nih.gov/pubmed/36330464
http://dx.doi.org/10.3389/fonc.2022.1023959

Ejemplares similares